AU2009231598B2 - Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same - Google Patents

Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same Download PDF

Info

Publication number
AU2009231598B2
AU2009231598B2 AU2009231598A AU2009231598A AU2009231598B2 AU 2009231598 B2 AU2009231598 B2 AU 2009231598B2 AU 2009231598 A AU2009231598 A AU 2009231598A AU 2009231598 A AU2009231598 A AU 2009231598A AU 2009231598 B2 AU2009231598 B2 AU 2009231598B2
Authority
AU
Australia
Prior art keywords
cells
immunogen
antigen
nucleic acid
encodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009231598A
Other languages
English (en)
Other versions
AU2009231598A1 (en
Inventor
Matthew P. Morrow
David B. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Publication of AU2009231598A1 publication Critical patent/AU2009231598A1/en
Application granted granted Critical
Publication of AU2009231598B2 publication Critical patent/AU2009231598B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009231598A 2008-04-04 2009-04-06 Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same Active AU2009231598B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4267408P 2008-04-04 2008-04-04
US61/042,674 2008-04-04
PCT/US2009/039648 WO2009124309A2 (en) 2008-04-04 2009-04-06 Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same

Publications (2)

Publication Number Publication Date
AU2009231598A1 AU2009231598A1 (en) 2009-10-08
AU2009231598B2 true AU2009231598B2 (en) 2015-03-12

Family

ID=41136128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009231598A Active AU2009231598B2 (en) 2008-04-04 2009-04-06 Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same

Country Status (8)

Country Link
US (6) US10071154B2 (enExample)
EP (1) EP2265715B1 (enExample)
JP (2) JP5873717B2 (enExample)
KR (1) KR101652767B1 (enExample)
CN (2) CN105535961A (enExample)
AU (1) AU2009231598B2 (enExample)
CA (1) CA2720168C (enExample)
WO (1) WO2009124309A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
JP6293485B2 (ja) * 2010-09-27 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コンセンサス抗原コンストラクトおよびそれらから作製されるワクチン、ならびにそれらを使用するマラリアの治療方法
US8906384B2 (en) * 2010-12-22 2014-12-09 The United States Of America As Represented By The Secretary Of Agriculture Antiviral activity of bovine type III interferon against foot-and-mouth disease virus
KR20220012403A (ko) * 2012-04-12 2022-02-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
RS61944B1 (sr) 2016-02-19 2021-07-30 Eiger Biopharmaceuticals Inc Lečenje infekcije hepatitis delta virusom sa interferonom lambda
EA201892124A1 (ru) 2016-12-02 2019-04-30 Дэвид Б. Уэйнер Днк-конструкции антител и способы их применения
CN107519482B (zh) * 2017-10-10 2023-06-02 中国人民解放军第四军医大学 一种白介素28a作为制备治疗银屑病药物中的应用
RU2759681C1 (ru) 2017-12-13 2021-11-16 Иновио Фармасьютикалз, Инк. Противораковые вакцины, нацеленные на boris, и способы их применения
CN111479590A (zh) 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向间皮素的癌症疫苗及其使用
CN111479583A (zh) 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向存活素的癌症疫苗和其用途
CA3084135C (en) 2017-12-13 2024-03-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
CN110964723B (zh) * 2019-11-08 2022-04-05 中山大学 一种用于预防和治疗流感病毒的质粒运载纳米颗粒及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165668A1 (en) * 2004-12-10 2006-07-27 Liu Linda N Genetically modified tumor cells as cancer vaccines

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) * 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
DE4090351T1 (de) 1989-03-08 1997-07-24 Health Research Inc Rekombinantes Pockenvirus-Wirtsselektionssystem
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69027313T2 (de) 1989-03-31 1997-01-23 Univ Washington Impfstoffe enthaltende avirulente phop-type mikroorganismen
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
CA2087132A1 (en) * 1992-01-31 1993-08-01 Michael S. Williams Stent capable of attachment within a body lumen
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) * 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
CA2745736C (en) 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
WO1998043702A2 (en) * 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US6241701B1 (en) * 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) * 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6055453A (en) * 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6135990A (en) * 1997-12-17 2000-10-24 University Of South Florida Electroporation device and method
US6778853B1 (en) * 1997-12-17 2004-08-17 University Of South Florida Electroporation device
US6120493A (en) * 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
EP1079890A4 (en) * 1998-05-08 2008-12-03 Genetronics Inc VASODILATION OF AN ELECTRICALLY INDUCED VESSEL
US20050037018A1 (en) 2003-06-20 2005-02-17 Innogentics N.V. HCV combination therapy
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
KR20010103788A (ko) * 1999-03-03 2001-11-23 멕코나시 에블린 에이치. 백신 및 유전자요법 조성물 및 이들의 제조 및 사용방법
JP2004515213A (ja) 2000-05-12 2004-05-27 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア ワクチン、免疫療法剤及びそれらの利用
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
ES2286128T3 (es) * 2000-06-30 2007-12-01 Zymogenetics, Inc. Proteina zcyto21 tipo interferon.
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
CA2503305A1 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
AU2004249191B2 (en) 2003-06-13 2011-01-06 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
JP4808157B2 (ja) 2003-08-07 2011-11-02 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９の均一な調製物
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
AU2005231476B2 (en) * 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
CN101031316A (zh) * 2004-07-29 2007-09-05 津莫吉尼蒂克斯公司 Il－28和il－29治疗癌症和自身免疫性疾病的用途
US7351689B2 (en) * 2004-07-29 2008-04-01 Zymogenetics, Inc. Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
US20060263368A1 (en) 2005-01-10 2006-11-23 Research Development Foundation Targeted chimeric molecules for cancer therapy
EP1838353A2 (en) * 2005-01-21 2007-10-03 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
AU2007313203B2 (en) * 2006-10-17 2012-08-16 Vgx Pharmaceuticals, Llc Electroporation devices and methods of using same for electroporation of cells in mammals
US9051369B2 (en) * 2007-09-20 2015-06-09 Commonwealth Scientific And Industrial Research Organisation Avian cytokines and genetic sequences encoding same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165668A1 (en) * 2004-12-10 2006-07-27 Liu Linda N Genetically modified tumor cells as cancer vaccines

Also Published As

Publication number Publication date
JP5873717B2 (ja) 2016-03-01
EP2265715A4 (en) 2013-05-15
US10646563B2 (en) 2020-05-12
US20110104105A1 (en) 2011-05-05
CA2720168C (en) 2024-04-30
US9744229B2 (en) 2017-08-29
EP2265715A2 (en) 2010-12-29
US10071154B2 (en) 2018-09-11
EP2265715B1 (en) 2016-12-28
CA2720168A1 (en) 2009-10-08
JP2011517938A (ja) 2011-06-23
CN102016023A (zh) 2011-04-13
AU2009231598A1 (en) 2009-10-08
WO2009124309A2 (en) 2009-10-08
US11998598B2 (en) 2024-06-04
JP2015061878A (ja) 2015-04-02
US11027009B2 (en) 2021-06-08
US20210330784A1 (en) 2021-10-28
US20140335111A1 (en) 2014-11-13
KR101652767B1 (ko) 2016-08-31
CN105535961A (zh) 2016-05-04
WO2009124309A3 (en) 2010-01-07
US20190076520A1 (en) 2019-03-14
KR20110004417A (ko) 2011-01-13
US20200268876A1 (en) 2020-08-27
US20240307527A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US20240307527A1 (en) Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
EP1976871B1 (en) Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same
AU2004251070B2 (en) Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US9629907B2 (en) Compositions for and methods of inducing mucosal immune responses
US9278128B2 (en) Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
EP1633372B1 (en) Vaccines, immunotherapeutics and methods for using the same
HK1156361A (en) Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)